Pancreatic Cancer Research

ResearcherCardiff UniversityActive in the last 2 years

Alan L. Parker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9302-1761; OpenAlex author ID A5077500117. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-024-02869-3↗
  2. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Co-author DOI 10.1038/s41598-019-49150-9↗
  3. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-17-0671↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luned M. Badder · 1 shared paper, 2024 · strength 0.22
  2. Beatriz Salvador-Barberó · 1 shared paper, 2024 · strength 0.22
  3. Y. K. Stella Man · 2 shared papers, 2018–2019 · strength 0.19
  4. Gunnel Halldén · 2 shared papers, 2018–2019 · strength 0.19
  5. Elisabete Carapuça · 1 shared paper, 2019 · strength 0.11
  6. Constantia Pantelidou · 1 shared paper, 2018 · strength 0.09
  7. John F. Marshall · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.